A Candidate Dengue Vaccine- Current Status
نویسندگان
چکیده
منابع مشابه
“Current Dengue Vaccine Status”
As the impact of dengue expands, a safe and effective vaccine will benefit the world greatly. Recent progress and novel approaches have advanced the field, but many challenges and unanswered questions remain for dengue vaccine developers. The most advanced dengue vaccine candidate, a chimeric yellow fever dengue (CYD) tetravalent vaccine, was the first dengue vaccine tested in a field efficacy ...
متن کاملA Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.
Dengue virus (DENV) represents a rapidly expanding global health threat, with approximately 40% of the world’s population now living in >100 countries at risk for DENV transmission, including the United States [1, 2]. In 2010, an estimated 390 million DENV infections occurred worldwide, of which 96 million were symptomatic [3]. DENV infections produce a spectrum of clinical disease. This includ...
متن کاملCurrent status of smallpox vaccine.
To the Editor: The possible use of smallpox virus as a weapon by terrorists has stimulated growing international concern and led to a recent review by the World Health Organization of the global availability of smallpox vaccine. This review found approximately 60 million doses worldwide, with little current vaccine manufacture, although limited vaccine seed remains available (1). Ongoing discus...
متن کاملChimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
We have constructed a chimeric yellow fever/dengue (YF/DEN) virus, which expresses the premembrane (prM) and envelope (E) genes from DEN type 2 (DEN-2) virus in a YF virus (YFV-17D) genetic background. Immunization of BALB/c mice with this chimeric virus induced a CD8 T-cell response specific for the DEN-2 virus prM and E proteins. This response protected YF/DEN virus-immunized mice against let...
متن کاملCurrent status of Pseudomonas aeruginosa vaccine.
Pseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained market authorization. The understanding of P. aeruginosa p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: TAJ: Journal of Teachers Association
سال: 2018
ISSN: 2408-8854,1019-8555
DOI: 10.3329/taj.v28i1.39038